NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

CFRA analyst Wan Nurhayati revised the price target for Novo Nordisk (NYSE:NVO) shares, reducing it to $90 from the previous target of $122. Despite the price target cut, the analyst retained a Hold ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Medicare to negotiate prices for Ozempic, Wegovy, and 13 other drugs, potentially saving billions for taxpayers.

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Feeding this momentum, the company saw a rapid acceleration of GenAI adoption over the past year. Over 20% of customers now use Dataiku to integrate GenAI into their business and data workflows, with ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...